- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Crackles.
Displaying page 1 of 3.
EudraCT Number: 2008-006437-26 | Sponsor Protocol Number: 1555 | Start Date*: 2008-06-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
Full Title: Effect of montelukast on lung function in children younger than 2 years with wheezing. | |||||||||||||
Medical condition: Recurrent wheezing | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003511-63 | Sponsor Protocol Number: IJG-PEN-2012 | Start Date*: 2013-03-01 |
Sponsor Name:IDIAP Jordi Gol | ||
Full Title: Efficacy of high doses of oral penicillin V versus high dose amoxicillin in the treatment of non-severe pneumonia treated at the adult community.PENIPNEUMO Study | ||
Medical condition: patients between 18-65 years with lower respiratory tract infection and radiologically confirmed diagnosis of pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000809-36 | Sponsor Protocol Number: CAP-IT | Start Date*: 2016-09-30 |
Sponsor Name:Medical Research Council Clinical Trials Unit at UCL | ||
Full Title: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial. | ||
Medical condition: Pneumonia | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001873-10 | Sponsor Protocol Number: P160929J | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR. A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic duration treatment strategy ... | |||||||||||||
Medical condition: Community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002841-23 | Sponsor Protocol Number: ALX0171-C104 | Start Date*: 2014-09-22 | |||||||||||
Sponsor Name:Ablynx NV | |||||||||||||
Full Title: A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-la... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Lower Respiratory Tract Infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) BE (Completed) ES (Completed) EE (Prematurely Ended) LV (Prematurely Ended) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002403-13 | Sponsor Protocol Number: Ularitide-1502 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:PDL BioPharma Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure | |||||||||||||
Medical condition: Acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023529-39 | Sponsor Protocol Number: RHM CHI 0548 | Start Date*: 2011-02-18 |
Sponsor Name:Southampton University Hopsitals NHS Trust | ||
Full Title: Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis – a phase 2 pilot study | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002060-31 | Sponsor Protocol Number: WHOCOVID-19coreprotocol | Start Date*: 2020-06-22 |
Sponsor Name:Masaryk University | ||
Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001243-15 | Sponsor Protocol Number: S63874 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:UZLeuven | |||||||||||||
Full Title: Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002324-15 | Sponsor Protocol Number: P01092 | Start Date*: 2007-09-04 | |||||||||||
Sponsor Name:University of East Anglia | |||||||||||||
Full Title: The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia | |||||||||||||
Medical condition: Idiopathic Interstitial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001433-83 | Sponsor Protocol Number: IMPROVE-AHF | Start Date*: 2015-01-15 | |||||||||||
Sponsor Name:Fundación INCLIVA | |||||||||||||
Full Title: Loop Diuretics Dosage in Patients with Acute Heart Failure and Renal Failure: Conventional versus Carbohydrate Antigen 125 guided Strategy | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001654-21 | Sponsor Protocol Number: KKS-279 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Justus-Liebig-University Gießen | |||||||||||||
Full Title: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002619-10 | Sponsor Protocol Number: OP-634-001 | Start Date*: 2004-11-10 | |||||||||||
Sponsor Name:Oscient Pharmaceuticals | |||||||||||||
Full Title: A Phase IIIb, Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin 320 mg Once Daily for 5 Days Versus Oral Gemifloxacin 320 mg Once Da... | |||||||||||||
Medical condition: Mild to moderate community acquired bacterial pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001670-84 | Sponsor Protocol Number: A 093 | Start Date*: 2007-09-12 | |||||||||||
Sponsor Name:Jassen-Cilag International NV | |||||||||||||
Full Title: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure | |||||||||||||
Medical condition: Acute Decompensated Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) LT (Completed) DE (Completed) GR (Completed) SE (Completed) NL (Completed) BG (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005213-11 | Sponsor Protocol Number: NES103694 | Start Date*: 2005-03-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with a... | |||||||||||||
Medical condition: Acute decompensated heart failure (adHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) IE (Completed) SK (Completed) HU (Prematurely Ended) IS (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) DK (Completed) LV (Completed) EE (Completed) FI (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001714-96 | Sponsor Protocol Number: R2222-RSV-1332 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ... | |||||||||||||
Medical condition: Medically attended respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001262-35 | Sponsor Protocol Number: D1690C00078 | Start Date*: 2023-02-09 | |||||||||||
Sponsor Name:The Brigham and Women's Hospital, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been St... | |||||||||||||
Medical condition: The study is evaluating the effect of In-hospital initiation of dapagliflozin in patients who have been stabilized during hospitalization for Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000936-23 | Sponsor Protocol Number: C20-15 | Start Date*: 2020-03-09 |
Sponsor Name:INSERM | ||
Full Title: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults | ||
Medical condition: COVID-19 - Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - Illness of any durat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) BE (Completed) AT (Completed) PT (Completed) SK (Completed) CZ (Completed) NO (Prematurely Ended) IE (Prematurely Ended) HU (Completed) ES (Ongoing) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003301-26 | Sponsor Protocol Number: IAFIPF001 | Start Date*: 2013-09-20 | |||||||||||
Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF) | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002011-21 | Sponsor Protocol Number: MARACOVID | Start Date*: 2020-06-02 |
Sponsor Name:Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor y Sureste (FIIB) | ||
Full Title: Bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (CO... | ||
Medical condition: COVID-19 Pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
